Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)

  1. Sehouli, J.
  2. Chekerov, R.
  3. Reinthaller, A.
  4. Richter, R.
  5. Gonzalez-Martin, A.
  6. Harter, P.
  7. Woopen, H.
  8. Petru, E.
  9. Hanker, L.C.
  10. Keil, E.
  11. Wimberger, P.
  12. Klare, P.
  13. Kurzeder, C.
  14. Hilpert, F.
  15. Belau, A.K.
  16. Zeimet, A.
  17. Bover-Barcelo, I.
  18. Canzler, U.
  19. Mahner, S.
  20. Meier, W.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2016

Alea: 27

Zenbakia: 12

Orrialdeak: 2236-2241

Mota: Artikulua

DOI: 10.1093/ANNONC/MDW418 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus